Micro-cost Analysis of ALK Rearrangement Testing by FISH to Determine Eligibility for Crizotinib Therapy in NSCLC: Implications for Cost Effectiveness of Testing and Treatment

Break-apart fluorescence in situ hybridization (FISH) is the gold standard test for anaplastic lymphoma kinase (ALK) gene rearrangement. However, this methodology often is assumed to be expensive and potentially cost-prohibitive given the low prevalence of ALK-positive non-small cell lung cancer (NS...

Descripción completa

Detalles Bibliográficos
Autores principales: Parker, David, Belaud-Rotureau, Marc-Antoine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Libertas Academica 2014
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4260793/
https://www.ncbi.nlm.nih.gov/pubmed/25520569
http://dx.doi.org/10.4137/CMO.S19236

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4260793/
https://www.ncbi.nlm.nih.gov/pubmed/25520569
http://dx.doi.org/10.4137/CMO.S19236

Ejemplares similares